Intl Stem Cell Corp (ISCO) 0.0601 $ISCO
International Stem Cell Corporation Announces Completion of Cell Bank for Parkinson's Disease Clinical Trial
Marketwired - Tue Feb 03, 7:32AM CST
International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, today announced that the Company has completed manufacturing of the cell bank of clinical-grade human neural stem cells using its patented process for the recently announced phase 1/2a clinical trial in Parkinson's disease. The cell bank contains over 2.6 billion human cells, sufficient to meet the company's foreseeable clinical trial requirements.
International Stem Cell to launch Parkinson's Disease phase 1/2a clinical study in Australia following successful completion of preclinical studies
M2 - Fri Jan 30, 11:14PM CST
Biotechnology company International Stem Cell (OtherOTC:ISCO) said on Thursday that it intends to start the phase 1/2a clinical study of its cell therapy for the treatment of Parkinson's disease in Australia within the next few months.
International Stem Cell Corporation to Conduct Parkinson's Disease Clinical Study in Australia
Marketwired - Thu Jan 29, 7:30AM CST
International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, today announced that the company has completed the required preclinical studies and plans to begin the phase 1/2a clinical study of the company's cell therapy for the treatment of Parkinson's disease in Australia within the next few months.
International Stem Cell Corporation to Present at Biotech Showcase(TM) 2015
Marketwired - Wed Jan 07, 7:31AM CST
International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, announced today that the Company's Chief Financial Officer, Mr. Jay Novak, Chief Scientific Officer, Ruslan Semechkin Ph.D., and Executive Vice President, Simon Craw Ph.D. will attend the Biotech Showcase(TM) 2015 Conference being held in San Francisco, CA from January 12 through 14, 2015. Dr. Craw will present a corporate overview.
Brainstorm Cell up on clinical trial results
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 9:25AM CST
FCSC: 4.75 (+0.50), PSTI: 2.91 (+0.01), NBS: 3.78 (+0.14), STEM: 1.09 (-0.01), BCLI: 3.86 (-0.02), CUR: 3.41 (+0.13)
International Stem Cell Corporation Wins EU Patent Ruling
Marketwired - Thu Dec 18, 11:35AM CST
International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that the Court of Justice of the European Union (CJEU), the European Union's highest court, has ruled in favor of the Company and that the Company's core technology patent applications are not covered by the prohibition on patenting embryonic stem cells. This ruling confirms the opinion of the Advocate General published in July 2014.
International Stem Cell Corporation Ranked as One of America's Fastest Growing Companies by Deloitte
Marketwired - Tue Dec 16, 7:31AM CST
International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, announced that ISCO has been included in the 2014 Technology Fast 500(TM) ranking of the fastest growing North American companies by Deloitte, one of the world's largest and well-respected organizations providing audit, tax, consulting, and financial advisory services in more than 150 countries.
Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2014
M2 - Wed Dec 10, 5:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/vv3g4v/alpha) has announced the addition of the "Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Alpha- Antitrypsin Deficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alpha- Antitrypsin Deficiency and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Alpha- Antitrypsin Deficiency - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Alpha- Antitrypsin Deficiency pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Applied Genetic Technologies Corporation - Arrowhead Research Corporation - Carolus Therapeutics - Cevec Pharmaceuticals - Dicerna Pharmaceuticals - Grifols - iBio - International Stem Cell Corporation - Intrexon Corporation - Kamada - OrphageniX - Polyphor - rEVO Biologics - Sangamo BioSciences For more information visit http://www.researchandmarkets.com/research/vv3g4v/alpha
DRNA: 21.30 (-0.06), ARWR: 6.77 (+0.21), SGMO: 15.40 (+0.14), XON: 39.30 (+1.05), RBIO: ()
Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/w5mzsz/retinitis) has announced the addition of the "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Retinitis Pigmentosa (Retinitis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa (Retinitis) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Retinitis Pigmentosa (Retinitis) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Retinitis Pigmentosa (Retinitis) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Acucela - Amarantus Bioscience - Applied Genetic - Asklepios BioPharmaceutical - BBB Therapeutics - BioDiem - DNAVEC - Dompe Farmaceutici - Genable Technologies - GenSight Biologics - Grupo Ferrer Internacional - International Stem Cell Corporation - Mimetogen - NeoStem - Neurotech - Ocata - Orphagen - QLT - R-Tech Ueno - ReGenX Biosciences - ReNeuron - Sanofi - Shire For more information visit http://www.researchandmarkets.com/research/w5mzsz/retinitis
Could Pinky the “Super Mouse” End Alzheimer’s?
Ray Blanco - Daily Reckoning - Fri Dec 05, 2:18PM CST
This post Could Pinky the “Super Mouse” End Alzheimer’s? appeared first on Daily Reckoning . Biotech stocks delivered triple-digit returns throughout the ’80s and ’90s. But it’s been a decade since we’ve seen similar results....
CUR: 3.41 (+0.13)
International Stem Cell Corporation to Present Preclinical Parkinson's Disease Data at Neuroscience 2014
Marketwired - Tue Nov 18, 11:26PM CST
International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, announced today preclinical data from its Parkinson's disease program. ISCO's Chief Scientific Officer Ruslan Semechkin, Ph.D., will discuss the data at the "Advances Through Stem Cell Research" press conference at the Society for Neuroscience's annual meeting at 10 a.m. on Nov. 18 in Washington, D.C.
International Stem Cell Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 14, 3:05PM CST
International Stem Cell beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 9:51AM CST
International Stem Cell Corporation Announces Record Revenues and Significant Progress in R&D
Marketwired - Thu Nov 13, 7:32AM CST
International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell based therapies and biomedical products today provided a business update and announced financial results for the three and nine months ended September 30, 2014.
International Stem Cell Corporation's Parkinson's Program to Be Highlighted at the Society for Neuroscience Annual Meeting
Marketwired - Tue Nov 11, 7:31AM CST
International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that the Company has been selected to present at the "Advances in Stem Cell Research" hot topics press conference at Neuroscience 2014, the Society for Neuroscience's annual meeting in Washington D.C., at 10:00 a.m. EST on November 18, 2014.
ISCO reports November 14
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 8:06AM CST
International Stem Cell Corporation to Host Third Quarter 2014 Business Update and Financial Results Conference Call at 11:00 am ET on Friday, November 14, 2014
Marketwired - Fri Nov 07, 7:31AM CST
International Stem Cell Corporation (OTCQB: ISCO) a California-based biotechnology company developing novel stem cell based therapies and biomedical products announced today that it will host a conference call on Friday, November 14, 2014 to provide a business update and discuss its financial results for the three and nine months ended September 30, 2014.
International Stem Cell Corporation Announces Completion of Cell Bank for Parkinson's Disease Clinical Trial
Marketwired - Tue Feb 03, 7:32AM CST
International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, today announced that the Company has completed manufacturing of the cell bank of clinical-grade human neural stem cells using its patented process for the recently announced phase 1/2a clinical trial in Parkinson's disease. The cell bank contains over 2.6 billion human cells, sufficient to meet the company's foreseeable clinical trial requirements.
International Stem Cell to launch Parkinson's Disease phase 1/2a clinical study in Australia following successful completion of preclinical studies
M2 - Fri Jan 30, 11:14PM CST
Biotechnology company International Stem Cell (OtherOTC:ISCO) said on Thursday that it intends to start the phase 1/2a clinical study of its cell therapy for the treatment of Parkinson's disease in Australia within the next few months.
International Stem Cell Corporation to Conduct Parkinson's Disease Clinical Study in Australia
Marketwired - Thu Jan 29, 7:30AM CST
International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, today announced that the company has completed the required preclinical studies and plans to begin the phase 1/2a clinical study of the company's cell therapy for the treatment of Parkinson's disease in Australia within the next few months.
International Stem Cell Corporation to Present at Biotech Showcase(TM) 2015
Marketwired - Wed Jan 07, 7:31AM CST
International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, announced today that the Company's Chief Financial Officer, Mr. Jay Novak, Chief Scientific Officer, Ruslan Semechkin Ph.D., and Executive Vice President, Simon Craw Ph.D. will attend the Biotech Showcase(TM) 2015 Conference being held in San Francisco, CA from January 12 through 14, 2015. Dr. Craw will present a corporate overview.
Brainstorm Cell up on clinical trial results
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 9:25AM CST
FCSC: 4.75 (+0.50), PSTI: 2.91 (+0.01), NBS: 3.78 (+0.14), STEM: 1.09 (-0.01), BCLI: 3.86 (-0.02), CUR: 3.41 (+0.13)
International Stem Cell Corporation Wins EU Patent Ruling
Marketwired - Thu Dec 18, 11:35AM CST
International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that the Court of Justice of the European Union (CJEU), the European Union's highest court, has ruled in favor of the Company and that the Company's core technology patent applications are not covered by the prohibition on patenting embryonic stem cells. This ruling confirms the opinion of the Advocate General published in July 2014.
International Stem Cell Corporation Ranked as One of America's Fastest Growing Companies by Deloitte
Marketwired - Tue Dec 16, 7:31AM CST
International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, announced that ISCO has been included in the 2014 Technology Fast 500(TM) ranking of the fastest growing North American companies by Deloitte, one of the world's largest and well-respected organizations providing audit, tax, consulting, and financial advisory services in more than 150 countries.
Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2014
M2 - Wed Dec 10, 5:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/vv3g4v/alpha) has announced the addition of the "Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Alpha- Antitrypsin Deficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alpha- Antitrypsin Deficiency and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Alpha- Antitrypsin Deficiency - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Alpha- Antitrypsin Deficiency pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Applied Genetic Technologies Corporation - Arrowhead Research Corporation - Carolus Therapeutics - Cevec Pharmaceuticals - Dicerna Pharmaceuticals - Grifols - iBio - International Stem Cell Corporation - Intrexon Corporation - Kamada - OrphageniX - Polyphor - rEVO Biologics - Sangamo BioSciences For more information visit http://www.researchandmarkets.com/research/vv3g4v/alpha
DRNA: 21.30 (-0.06), ARWR: 6.77 (+0.21), SGMO: 15.40 (+0.14), XON: 39.30 (+1.05), RBIO: ()
Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/w5mzsz/retinitis) has announced the addition of the "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Retinitis Pigmentosa (Retinitis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa (Retinitis) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Retinitis Pigmentosa (Retinitis) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Retinitis Pigmentosa (Retinitis) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Acucela - Amarantus Bioscience - Applied Genetic - Asklepios BioPharmaceutical - BBB Therapeutics - BioDiem - DNAVEC - Dompe Farmaceutici - Genable Technologies - GenSight Biologics - Grupo Ferrer Internacional - International Stem Cell Corporation - Mimetogen - NeoStem - Neurotech - Ocata - Orphagen - QLT - R-Tech Ueno - ReGenX Biosciences - ReNeuron - Sanofi - Shire For more information visit http://www.researchandmarkets.com/research/w5mzsz/retinitis
Could Pinky the “Super Mouse” End Alzheimer’s?
Ray Blanco - Daily Reckoning - Fri Dec 05, 2:18PM CST
This post Could Pinky the “Super Mouse” End Alzheimer’s? appeared first on Daily Reckoning . Biotech stocks delivered triple-digit returns throughout the ’80s and ’90s. But it’s been a decade since we’ve seen similar results....
CUR: 3.41 (+0.13)
International Stem Cell Corporation to Present Preclinical Parkinson's Disease Data at Neuroscience 2014
Marketwired - Tue Nov 18, 11:26PM CST
International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, announced today preclinical data from its Parkinson's disease program. ISCO's Chief Scientific Officer Ruslan Semechkin, Ph.D., will discuss the data at the "Advances Through Stem Cell Research" press conference at the Society for Neuroscience's annual meeting at 10 a.m. on Nov. 18 in Washington, D.C.
International Stem Cell Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 14, 3:05PM CST
International Stem Cell beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 9:51AM CST
International Stem Cell Corporation Announces Record Revenues and Significant Progress in R&D
Marketwired - Thu Nov 13, 7:32AM CST
International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell based therapies and biomedical products today provided a business update and announced financial results for the three and nine months ended September 30, 2014.
International Stem Cell Corporation's Parkinson's Program to Be Highlighted at the Society for Neuroscience Annual Meeting
Marketwired - Tue Nov 11, 7:31AM CST
International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that the Company has been selected to present at the "Advances in Stem Cell Research" hot topics press conference at Neuroscience 2014, the Society for Neuroscience's annual meeting in Washington D.C., at 10:00 a.m. EST on November 18, 2014.
ISCO reports November 14
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 8:06AM CST
International Stem Cell Corporation to Host Third Quarter 2014 Business Update and Financial Results Conference Call at 11:00 am ET on Friday, November 14, 2014
Marketwired - Fri Nov 07, 7:31AM CST
International Stem Cell Corporation (OTCQB: ISCO) a California-based biotechnology company developing novel stem cell based therapies and biomedical products announced today that it will host a conference call on Friday, November 14, 2014 to provide a business update and discuss its financial results for the three and nine months ended September 30, 2014.
